Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita

Bone Marrow Transplantation

Volumn 31, Issue 10, 2003, Pages 847-850

  Dror, Y ^a   Freedman, M H ^a   Leaker, M ^b   Verbeek, J ^c   Armstrong, C A ^a   Saunders, F E ^a   Doyle, J J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Children's Hospital   (Canada)

^c Timmins and District Hospital   (Canada)

Author keywords

Congenital aplastic anemia; Dyskeratosis congenita; Fludarabine; Hematopoietic stem cell transplantation; Non myeloablative

Indexed keywords

ACICLOVIR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN; METHOTREXATE; PENTAMIDINE; PREDNISONE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BLOOD EXAMINATION; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DONOR; DOSE RESPONSE; DRUG TOLERABILITY; DYSKERATOSIS CONGENITA; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LABORATORY TEST; LEUKOPLAKIA; MALE; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SKIN BRUISING; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; CHILD, PRESCHOOL; CYCLOSPORINE; DYSKERATOSIS CONGENITA; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; STEM CELL TRANSPLANTATION;

EID: 0038621756     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703931     Document Type: Article

References (35)

1. Drachtman RA, Alter BP. Dyskeratosis congenita: clinical and genetic heterogeneity. Report of a new case and review of the literature. Am J Pediatr Hematol Oncol 1992; 14: 297-304.
2. Knight S, Vulliamy T, Copplestone A et al. Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br J Haematol 1998; 103: 990-996.
3. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000; 110: 768-779.
4. Rocha V, Devergie A, Socié G et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1998; 103: 243-248.
5. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
6. Horwitz ME, Barrett AJ, Brown MR et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001; 344: 881-888.
7. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
8. Nagler A, Aker M, Or R et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 2001; 29: 362-370.
9. Chan KW, Li CK, Worth LL et al. A fludarabine-based conditioning regimen for severe aplastic anemia. Bone Marrow Transplant 2001; 27: 125-128.
10. Amrolia P, Gaspar HB, Hassan A et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000; 96: 1239-1246.
11. Knight SW, Heiss NS, Vulliamy TJ et al. X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. Am J Human Genetics 1999; 65: 50-8.
12. Vulliamy T, Marrone A, Goldman F et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001; 413: 432-435.
13. Bryant E, Martin PJ. Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ (eds) Hematopoietic Cell Transplantation, 2nd edn. Blackwell Science: Boston, 1999, pp. 197-206.
14. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
15. Anasetti C, Beatty PG, Storb R et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990; 29: 79-91.
16. Berthou C, Devergie A, D'Agay MF et al. Late vascular complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1991; 79: 335-336.
17. Dokal I, Bungey J, Williamson P, et al. Oscier D, Hows J, Luzzatto L. Dyskeratosis congenita fibroblasts are abnormal and have unbalanced chromosomal rearrangements. Blood 1992; 80: 3090-3096.
18. Forni GL, Melevendi C, Jappelli S et al. Dyskeratosis congenita: unusual presenting features within a kindred. Pediatric Hematol Oncol 1993; 10: 145-149.
19. Lau YL, Ha SY, Chan CF et al. Bone marrow transplant for dyskeratosis congenita. [letter]. Br J Haematol 1999; 105: 571.
20. Yabe M, Yabe H, Hattori K et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 389-392.
21. Phillips RJ, Judge M, Webb D et al. Dyskeratosis congenita: delay in diagnosis and successful treatment of pancytopenia by bone marrow transplantation. Br J Dermatol 1992; 127: 278-280.
22. Langston AA, Sanders JE, Deeg HJ et al. Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Br J Haematol 1996; 92: 758-765.
23. Ghavamzadeh A, Alimoghadam K, Nasseri P et al. Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation. Bone Marrow Transplant 1999; 23: 299-301.
24. Shaw PH, Haut PR, Olszewski M et al. Kletzel M. Hematopoietic stem-cell transplantation using unrelated cord-blood versus matched sibling marrow in pediatric bone marrow failure syndrome: one center's experience. Pediatr Transplant 1999; 3: 315-321.
25. Conter V, Johnson EL, Paolucci P et al. Bone marrow transplantation for aplastic anemia associated with dyskeratosis congenita. Am J Pediatric Hematol/Oncol 1988; 10: 99-102.
26. Catani L, Gugliotta L, Vianelli N et al. Endothelium and bone marrow transplantation. Bone Marrow Transplant 1996; 17: 277-280.
27. Dokal I, Manning R, Laffan M. Elevated levels and multimer pattern of von Willebrand factor in patients with dyskeratosis congenita [abstract # 122]. Br J Haematol 1995; 89(S1): 33.
28. Paul SR, Perez-Atayde A, Williams DA. Interstitial pulmonary disease associated with dyskeratosis congenita. Am J Pediatr Hematol/Oncol 1992; 14: 89-92.
29. Gluckman E, Auerbach AD, Horowitz MM et al. Bone marrow transplantation for Fanconi anemia. Blood 1995; 86: 2856-2862.
30. Dokal I, Luzzatto L. Dyskeratosis congenita is a chromosomal instability disorder. Leuk Lymphoma 1994; 15: 1-7.
31. Vulliamy TJ, Knight SW, Mason PJ et al. Very short telomeres in the peripheral blood of patients with x-linked and autosomal dyskeratosis congenita. Blood Cells Mol Dis 2001; 27: 353-357.
32. Wynn R, Thornley I, Freedman M et al. Telomere shortening in leucocyte subsets of long-term survivors of allogeneic bone marrow transplantation. Br J Haematol 1999; 105: 997-1001.
33. Kapelushnik J, Or R, Slavin S et al. A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia. Bone Marrow Transplant 1997; 20: 1109-1110.
34. Aker M, Varadi G, Slavin S et al. Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi anemia. J Pediatric Hematol Oncol 1999; 21: 237-239.
35. Mahmoud HK, Schaefer UW, Schmidt CG et al. Marrow transplantation for pancytopenia in dyskeratosis congenita. Blut 1985; 51: 57-60.